118
Participants
Start Date
December 18, 2019
Primary Completion Date
June 2, 2025
Study Completion Date
December 31, 2026
Belantamab mafodotin
Selected doses of belantamab mafodotin will be administered as intravenous infusion.
Bortezomib
Bortezomib will be administered subcutaneously or intravenously approximately 1 hour after the belantamab mafodotin infusion until Cycle 8.
Lenalidomide
Lenalidomide will be administered as 25 or 10 mg orally, depending upon renal function.
Dexamethasone
Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.
GSK Investigational Site, Newcastle
GSK Investigational Site, Fitzroy
GSK Investigational Site, Clayton
GSK Investigational Site, Schwerin
GSK Investigational Site, Hamburg
GSK Investigational Site, Madrid
GSK Investigational Site, Charlotte
GSK Investigational Site, Pozuelo de AlarcOn Madr
GSK Investigational Site, Málaga
GSK Investigational Site, PamplonaNavarra
GSK Investigational Site, Santander
GSK Investigational Site, Bologna
GSK Investigational Site, Meldola FC
GSK Investigational Site, Madison
GSK Investigational Site, Westwood
GSK Investigational Site, Tübingen
GSK Investigational Site, Poitiers
GSK Investigational Site, Edmonton
GSK Investigational Site, London
GSK Investigational Site, Dresden
GSK Investigational Site, Lublin
GSK Investigational Site, Poznan
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Badalona
GSK Investigational Site, Barcelona
GSK Investigational Site, Leicester
GSK Investigational Site, Oxford
GSK Investigational Site, Southampton
Lead Sponsor
GlaxoSmithKline
INDUSTRY